Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y1VT
|
||||
| Former ID |
DIB013029
|
||||
| Drug Name |
VEGF-2 gene therapy
|
||||
| Synonyms |
PhVEGF165; VEGF-2 gene therapy (diabetic neuropathy/ critical limb ischemia); VEGF-2 gene therapy (diabetic neuropathy/ critical limb ischemia), Northwestern University
|
||||
| Indication | Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10:E11.40] | Phase 1 | [1] | ||
| Company |
St Elizabeths Medical Center of Boston Inc
|
||||
| Target and Pathway | |||||
| Target(s) | VEGF receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| References | |||||
| REF 1 | Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998 Mar 31;97(12):1114-23. | ||||
| REF 2 | Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996 Aug 10;348(9024):370-4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.